ArticleFrontiers in medicine2025
Explainable machine learning for predicting distant metastases in renal cell carcinoma patients: a population-based retrospective study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning studies for predicting 5-year renal cell cancer survival: a multicenter study.Translational andrology and urology · 2025Article
- Machine learning prediction of overall survival in patients with cT1b renal cell carcinoma after surgical resection using the SEER database.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Distant metastasis is a key factor contributing to poor prognosis in renal cell carcinoma (RCC). Early prediction of metastasis is crucial for developing personalized treatment plans and improving patient outcomes. This study aimed to establish and validate a clinical prediction model for distant metastasis in RCC patients. Methods: Ten machine learning algorithms were employed to develop a predictive model for distant metastasis in RCC. Data from 51,566 RCC patients in The Surveillance, Epidemiology, and End Results (SEER) database (2010-2018) were used for model development, while 726 RCC patients from the First Hospital of Shanxi Medical University were selected for external validation. Hyperparameters were optimized using grid search and tenfold cross-validation. Model performance was assessed using metrics such as the area under the receiver operating characteristic curve (AUC), the area under the precision-recall curve (AUPRC), decision curve analysis, calibration curves, precision, and accuracy. Shapley additive explanations (SHAP) were used for model interpretation. The best-performing model was then used to create a web-based calculator to predict metastasis risk in RCC patients. Results: The study included 51,566 RCC patients, with 3,667 showing distant metastases. Logistic regression identified tumor size, grade, T-stage, N-stage, radiotherapy, chemotherapy, and surgery as independent risk factors. The Extreme Gradient Boosting (XGB) model demonstrated superior performance (AUC: 0.957, Accuracy: 0.898) in the training set and was validated externally (AUC: 0.742, Accuracy: 0.904). A web-based calculator was developed using the XGB model. Conclusion: This study designed and validated an XGB model using clinicopathologic data to predict the risk of distant metastasis in RCC patients, potentially aiding clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.